公开(公告)号：US11932630B2

公开(公告)日：2024-03-19

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian Xie

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof,




a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US20220348566A1

公开(公告)日：2022-11-03

申请号：US17716423

申请日：2022-04-08

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K45/06 ,  A61K31/4245 ,  A61K31/4439 ,  C07D413/14 ,  C07D471/04 ,  A61K31/436 ,  C07D401/14 ,  C07D401/12 ,  C07D257/04 ,  A61K31/41

Abstract: The present invention provides a compound of formula (I) or a pharmaceutically acceptable salt thereof; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US11426375B2

公开(公告)日：2022-08-30

申请号：US16854355

申请日：2020-04-21

Applicant: NOVARTIS AG

Inventor： Yongshuai Chai ,  Sven Erik Godtfredsen ,  Mark Kagan ,  Yugang Liu ,  Mahavir Prashad ,  Zhaoyin Wang ,  Saijie Zhu

IPC: A61K31/235 ,  A61K31/24 ,  A61K31/41 ,  A61K31/197 ,  A61P9/00 ,  A61K31/405 ,  C07C229/36 ,  C07C233/47 ,  C07C279/14 ,  C07D209/08

Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.

公开(公告)号：US20240199593A1

公开(公告)日：2024-06-20

申请号：US18426461

申请日：2024-01-30

Applicant: NOVARTIS AG

Inventor： Andreas Kordikowski ,  Yugang Liu ,  Rainer Martin Lüönd ,  Christian Markert ,  Wolfgang Miltz ,  Till Roehn ,  Carsten Spanka ,  Gebhard Thoma ,  Tian XIE

IPC: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

CPC classification number: C07D413/10 ,  A61K31/41 ,  A61K31/4245 ,  A61K31/436 ,  A61K31/4439 ,  A61K45/06 ,  C07D257/04 ,  C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D471/04

Abstract: The present invention provides a crystalline form of (S)-2-amino-3-(3-(4-((3-fluoro-5-(1H-pyrazol-5-yl)pyridin-2-yl)oxy)phenyl)-1H-pyrazol-1-yl)propan-1-ol, in its free form;

a method for manufacturing said crystalline form, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

公开(公告)号：US10668035B2

公开(公告)日：2020-06-02

申请号：US16388221

申请日：2019-04-18

Applicant: NOVARTIS AG

Inventor： Yongshuai Chai ,  Sven Erik Godtfredsen ,  Mark Kagan ,  Yugang Liu ,  Mahavir Prashad ,  Zhaoyin Wang ,  Saijie Zhu

IPC: C07D205/00 ,  A61K31/235 ,  A61K31/197 ,  A61P9/00 ,  C07C229/36 ,  A61K31/405 ,  C07D209/08 ,  A61K31/41 ,  C07C279/14 ,  C07C233/47

Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.

公开(公告)号：US20180344679A1

公开(公告)日：2018-12-06

申请号：US16006252

申请日：2018-06-12

Applicant: Novartis AG

Inventor： Lili Feng ,  Sven Erik Godtfredsen ,  Paul Allen Sutton ,  Mahavir Prashad ,  Michael J. Girgis ,  Bin Hu ,  Yugang Liu ,  Thomas J. Blacklock ,  Piotr Henryk Karpinski

IPC: A61K31/216 ,  C07D207/50 ,  C07D257/04 ,  C07C233/47 ,  A61K31/5415 ,  A61K31/41 ,  A61K31/4422 ,  A61K45/06

CPC classification number: A61K31/216 ,  A61K31/41 ,  A61K31/4422 ,  A61K31/5415 ,  A61K45/06 ,  A61K2300/00 ,  C07C233/47 ,  C07D207/50 ,  C07D257/04

Abstract: A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.